About Jecho Lab

Jecho Laboratories, Inc. (Jecho Lab) is a privately owned biopharmaceutical company that researches and develops innovative therapeutic biologics, including therapeutic monoclonal antibodies, cytokines, immunotoxins, and vaccines to treat a broad range of diseases and cancers.  Jecho Lab's headquarters and main facilities are in Frederick Maryland, USA, near the National Institute of Health (NIH).

 

Research and Development

Jecho Lab has an excellent research and development team, holding multiple patents, licenses, and propriety technologies.  In addition to its collaboration with various U.S research institutions, Jecho Lab is a strategic partner with Shanghai Jiaotong University (SJTU) School of Pharmacy in China. 

Jecho Lab includes several major groups: Drug Discovery, Process Development (PD), Analytical Development (AD), and Quality Units (QC and QA).  

Jecho Lab assesses current market conditions for bio-similar and novel biopharmaceuticals, and the drug discovery process begins when a viable market is determined.  Once optimized a drug, the Drug Discovery Group then hands it off to the Process Development Group to develop a scalable manufacturing process.  The Analytical Development Group develops analytical methods to ensure the process robustness and drug safety and efficacy.  The Quality Unit ensures regulatory compliance throughout the entire process. 

 

 

Jecho Lab, in collaboration with domestic and overseas manufacturing partners, focuses on developing bio-therapeutic products and production processes, including novel drug candidates, bio-similars, and innovative bio-manufacturing technologies.  Jecho Lab serves as an upstream partner to manufacturers, providing bio-similar and novel biopharmaceutical products and processes.  Jecho Lab has entered a partnership with Jecho Biopharmaceuticals (Jecho Biopharma) in Tianjin, China.  The products, including monoclonal antibodies, recombinant proteins, and vaccines, will be manufactured and marketed worldwide. 

 

New Pilot and Manufacturing Facility

Jecho is currently establishing a new multi-products pilot and clinical manufacturing facility.

The first phase of the planned site will include a 250-500L pilot scale line and four 3,000-5,000L production lines. Corresponding purification capacity will also be built on-site.  

 

 

In phase II, additional six or more 5,000L production lines will be added. Optional 10,000 to 20,000 L production capacities will be installed as needed.

 

 

Partnership with Shanghai Jiao Tong University School of Pharmacy

Jecho Lab has entered a strategic partnership with Shanghai Jiao Tong University (SJTU) School of Pharmacy to develop novel biopharmaceutics. 

Jecho will help bring SJTU's scientific research discoveries into clinical studies.  Jecho will provide guidance and assistance in license acquisition of early stage development therapeutic agents and new technologies. Additionally, Jecho will make its US R&D facility available for training SJTU technical staff.